Heart attack stem cell therapy under Long-Term safety watch

NCT ID NCT07400458

Recruiting now Disease control Sponsor: Pharmicell Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 100 people who received Hearticellgram-AMI, a stem cell treatment for acute heart attacks, to see if any serious side effects appear years later. Researchers are watching for death, new cancers, or immune reactions. The goal is to confirm the treatment's long-term safety after it was already approved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hearticellgram-AMI (a cell therapy made from stem cells)
What this could lead to: If this study shows the treatment is safe over many years, it could support its continued use for heart attack recovery.
What could go wrong: This is a long-term safety follow-up, not a test of effectiveness. The treatment is already approved, but rare side effects may still emerge. The study is small (100 people) and observational, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYOCARDIAL INFARCTION

Contacts and locations

Locations

KIMHYUNSOO Clinic
RECRUITING

Seoul, Gangnam, 06017, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.